1 |
Havaldar, P. V., M. N. Sankpal, and R. P. Doddannavar (2000) Diphtheritic myocarditis: clinical and laboratory parameters of prognosis and fatal outcome. Annals of Tropical Paediatrics 20: 209-215.
|
2 |
Higashiyama, S., R. Iwamoto, K. Goishi, G. Raab, N. Taniguchi, M. Klagsbrun, and Mekada (1995) The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. The Journal of Cell Biology 128: 929-938.
DOI
ScienceOn
|
3 |
Holmes, R. K. (2000) Biology and molecular epidemiology of diphtheria toxin and the tox gene. The Journal of Infectious 181: S156-S167.
DOI
|
4 |
Honjo, T., Y. Nishizuka, and O. Hayashi (1968) Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. The Journal of Biological Chemistry 243: 3553-3555.
|
5 |
Iwamoto, R., S. Higashiyama, T. Mitamura, N. Taniguchi, M. Klagsbrun, and E. Mekada (1994) Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulatesfunctional receptors and diphtheria toxin sensitivity. The EMBO Journal 13: 2322-2330.
|
6 |
Jezek, J., D. Chen, L. Watson, J. Crawford, S. Perkins, A. Tyagi, and Jones-Braun (2009) A heat-stable hepatitis B vaccine formulation. Human Vaccines 5: 529-535.
DOI
ScienceOn
|
7 |
Uchida, T., A. M. Jr. Pappenheimer, and R. Greany (1973) Diphtheria toxin and related proteins: I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. The Journal of Biological Chemistry 248: 3838-3844.
|
8 |
Ulrich, J. T. and K. R. Myers (1995) Monophosphoryl lipid A as an adjuvant: past experiences and new directions. Pharmaceutical Biotechnology 6:495-524.
DOI
|
9 |
World Health Organization (2006) Vaccine-preventable Diseases: Monitoring System - Global Summary, World Health Organization, Geneva, Switzerland.
|
10 |
Johasen, P., L. Moon, H. Tamber, H. P. Merkle, B. Gander, and D. Sesardic (1999) Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18: 209-215.
DOI
ScienceOn
|
11 |
Johnson, V. G., D. Wilson, L. Greenfield, and R. J. Youle (1988) The role of the diphtheria toxin receptor in cytosol translocation. The Journal of Biological Chemistry 263: 1295-1300.
|
12 |
Johnson, V. G. and R. J. Youle (1989) A point mutation of proline 308 in diphtheria toxin B chain inhibits membrane translocation of toxin conjugates. The Journal of Biological Chemistry 264: 17739-17744.
|
13 |
Jones, E. E., R. J. Kim-Farley, M. Algunaid, M. A. Parvez, Y. A. Ballad, A. W. Hightower, W. A. Orenstein, and C. V. Broome (1985) Diphtheria: a possible foodborne outbreak in hodeida and yemen arab republic. Bulletin of the World Health Organization 63: 287-293.
|
14 |
Kaczorek, M., F. Delpeyroux, N. Chenciner, R. E. Streeck, J. R. Murphy, P. Boquet, and P. Tiollais (1983) Nucleotide sequence and expression of the diphtheria tox228 gene in Escherichia coli. Science 221: 855-858.
DOI
|
15 |
Yamaizumi, M., E. Mekada,T. Uchida, and Y. Okada (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15: 245-250.
DOI
ScienceOn
|
16 |
World Health Organization (2009) The Immunological Basis for Immunization Series Module 2: Diphtheria, World Health Organization, Geneva, Switzerland.
|
17 |
World Health Organization (2010) Vaccine-preventable Diseases: Monitoring System - Global Summary, World Health Organization, Geneva, Switzerland.
|
18 |
Wright, H. D., H. R. Shone, and J. R. Tucker (1941) Cross infection in diphtheria wards. Journal of Pathology and Bacteriology 52: 111-128.
DOI
|
19 |
Kaistha, J., J. Sokhey, S. Singh, S. Kumar, P. C. John, and N. C. Sharma (1996) Adjuvant effect of DEAE-dextran and tetanus toxoid on whole cell heat inactivated phenol preserved typhoid vaccine. Indian Journal of Pathology & Microbiology 39: 287-292.
|
20 |
Kageyama, T., M. Ohishi, S. Miyamoto, H. Mizushima, R. Iwamoto, and E. Mekada (2007) Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. Journal of Biochemistry 142: 95-104.
DOI
ScienceOn
|
21 |
Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nature Immunology 5: 190-198.
DOI
|
22 |
Lowenstein, E. (1909) Uber aktive schutzimpfung bei tetanus durch toxoide. Z. Hyg. InfektKr. 62: 491-508.
DOI
|
23 |
Murphy, J. R. (2011) Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxin 3: 294-308.
DOI
|
24 |
Mortimer, E. A. (1988) Diphtheria toxoid. pp. 31-44. In: S. A. Plotkin and E. A. Jr. Mortimer (eds.). Vaccines. W. B. Saunders Company. Philadelphia, USA.
|
25 |
Maa, Y. F., L. Zhao, L. G. Payne, and D. Chen (2003) Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. Journal of Pharmaceutical Sciences 92: 319-332.
DOI
ScienceOn
|
26 |
Matjila, M. J., T. C. Phohu, A. Banzhoff, S. Viviani, A. A. Hoosen, M. Bianchini, P. Nacci, C. W. Palweni, Podda, A., M. Whitfield, and S. Aspinall (2004) Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines. South African Medical journal 94: 43-46.
|
27 |
Mattos-Guaraldi, A. L., L. O. Moreira, P. V. Damasco, and R. Hirata Junior (2003) Diphtheria remains a threat to health in the developing world - an overview. Memorias do Instituto Oswaldo Cruz 98: 987-993.
DOI
ScienceOn
|
28 |
Maxwell, F., I. H. Maxwell, and L. M. Glode (1987) Cloning, sequence determination, and expression in transfected cells of the coding sequence for the tox 176 attenuated diphtheria toxin A chain. Molecular and Cellular Biology 7: 1576-1579.
|
29 |
Moyner, K. and G. Christiansen (1984) Comparison of gel filtration and ammonium sulphate precipitation in the purification of diphtheria toxin and toxoid, Acta pathologica, microbiologica, et immunologica Scandinavica, Immunology 92: 17-23.
|
30 |
Murdan, S., S. Somavarapu, A. C. Ross, H. O. Alpar, and M. C. Parker (2005) Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. International Journal of Pharmaceutics 296: 117-121.
DOI
|
31 |
Metz, B., W. Jiskoot, W. E. Hennink, D. J. Crommelin, and G. F. Kersten (2003) Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccine. Vaccine 22: 156-167.
DOI
ScienceOn
|
32 |
McCluskie, M. J., R. D. Weeratna, A. M. Krieg, and H. L. Davis (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19: 950-957.
DOI
ScienceOn
|
33 |
McNeela, E. A., I. Jabbal-Gill, L. Illum, M. Pizza, R. Rappuoli, A. Podda, D. J. Lewis, and K. H. Mills (2004) Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22: 909-914.
DOI
ScienceOn
|
34 |
McNeela, E. A., D. O'Connor, I. Jabbal-Gill, L. Illum, S. S. Davis, M. Pizza, S. Peppoloni, R. Rappuoli, and K. H. Mills (2000) A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19: 9-10.
DOI
|
35 |
Middaugh, J. P. (1979) Side-effects of diphtheria-tetaneus toxoid in adults. American Journal of Public Health 69: 246-249.
DOI
ScienceOn
|
36 |
Muttil, P., B. Pulliam, L. Garcia-Contreras, J. K. Fallon, C. Wang, A. J. Hickey, and D. A. Edwards (2010) Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. The AAPS journal 12: 699-707.
DOI
|
37 |
Naglich, J. G., J. E. Metherall, D. W. Russell, and L. Eidels (1992) Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69: 1051-1061.
DOI
ScienceOn
|
38 |
Pappenheimer, A. M. Jr (1977) Diphtheria toxin. Annual Review of Biochemistry 46: 69-94.
DOI
ScienceOn
|
39 |
Metz, B., G. F. Kersten, P. Hoogerhout, H. F. Brugghe, H. A. Timmermans, A. de Jong, H. Meiring, J. ten Hove, W. E. Hennink, D. J. Crommelin, and W. Jiskoot (2004) Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. The Journal of Biological Chemistry 279: 6235-6243.
|
40 |
Micoli, F., S. Rondini, I. Pisoni, D. Proietti, F. Berti, F. Costantino, R. Rappuoli, S. Szu, A. Saul, and L. B. Martin (2011) Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 29: 712-720.
DOI
ScienceOn
|
41 |
Mills, K. H., C. Cosgrove, E. A. McNeela, A. Sexton, R. Giemza, I. Jabbal-Gill, A. Church, W. Lin, L. Illum, and A. Podda (2003) Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin. Infection and Immunity 71: 726-732.
DOI
ScienceOn
|
42 |
Mokrousov, I. (2009) Corynebacterium diphtheriae: genome diversity, population structure and genotyping perspectives. Infection, Genetics and Evolution 9: 1-15.
DOI
ScienceOn
|
43 |
Peek, L. J., C. R. Middaugh, and C. Berkland (2001) Nanotechnology in vaccine delivery. Advanced Drug Delivery Reviews 60: 915-928.
|
44 |
Petre, J., M. Pizza, L. Nencioni, A. Podda, M. T. De Magistris, and R. Rappuoli (1996) The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Developments in Biological Standardization 87: 125-134.
|
45 |
Pizza, M., M. R. Fontana, V. Scarlato, and R. Rappuoli (1996) Genetic detoxification of bacterial toxins. Methods in Molecular Medicine 4: 91-109.
|
46 |
Milstien, J. B., S. M. Lemon, and P. F. Wright (1997) Development of a more thermostable poliovirus vaccine. The Journal of Infectious Disease 175: S247-S253.
DOI
|
47 |
Mitamura, T., T. Umata, F. Nakano, Y. Shishido, T. Toyoda, A. Itai, H. Kimura, and E. Mekada (1997) Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenensis. The Journal of Biological Chemistry 272: 27084-27090.
DOI
|
48 |
Porro, M., M. Saletti, L. Nencioni, L. Tagliaferri, and I. Marsili (1980) Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid. The Journal of Infectious Disease 142: 716-724.
DOI
ScienceOn
|
49 |
Pope, C. G. (1963) Development of knowledge of antitoxins. British Medical Bulletin 19: 230-234.
|
50 |
Popovic, T., I. K. Mazurova, A. Efstratiou, J. Vuopio-Varkila, M. W. Reeves, A. De Zoysa, T. Glushkevich, and P. Grimont (2000) Molecular epidemiology of diphtheria. The Journal of Infectious Disease 181: S168-S177.
DOI
|
51 |
Qiao, J., K. Ghani, and M. Caruso (2008) Diphtheria toxin mutant CRM 197 is an inhibitor of protein synthesis that induces cellular toxicity. Toxicon 51: 473-477.
DOI
ScienceOn
|
52 |
Anderson, P., J. Treanor, S. Porcelli, and M. Pichichero (2003) Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children. Vaccine 21: 1554-1559.
DOI
ScienceOn
|
53 |
Akama, K., S. Kameyama, S. Otani, S. Sadahiro, and R. Murata (1971) Reversion of toxicity of diphtheria toxoid. Japanese Journal of Medical Science & Biology 24: 183-187.
DOI
|
54 |
Amorij, J. P., T. A. Westra, W. L. Hinrichs, A. Huckriede, and H. W. Frijlink (2007) Towards an oral influenza vaccine: comparison between intragastric and intracolonicdelivery of influenza subunit vaccine in a murine model. Vaccine 26: 67-76.
DOI
ScienceOn
|
55 |
Anderson, D. G., W. Peng, A. Akinc, N. Hossain, A. Kohn, R. Padera, R. Langer, and J. A. Sawicki (2004) A polymer library approach to suicide gene therapy for cancer. Proceedings of the National Academy of Sciences of the United States of America 101: 16028-16033.
DOI
ScienceOn
|
56 |
Antoni, G., M. Bigio, G. Borri, M. C. Casagli, and P. Neri (1983) Purification of diphtheria toxin by chromatography on cibacron blue-sepharose. Experientia 39: 885-886.
DOI
ScienceOn
|
57 |
Ramon, G. (1926) Procedes pour accroitre la production des antitoxines. Annales de l'Institut Pasteur 40: 1-10.
|
58 |
Moreira, L. de O., A. F. Andrade, M. D. Vale, S. M. Souza, R. Jr. Hirata, L. M. Asad, N. R. Asad, L. H. Monteiro-Leal, J. O. Previato, and A. L. Mattos-Guaraldi (2003) Effects of iron limitation on adherence and cell surface carbohydrates of Corynebacterium diphtheriae strains. Applied and Environmental Microbiology 69: 5907-5913.
DOI
ScienceOn
|
59 |
Morris, R. E., A. S. Gerstein, P. F. Bonventre, and C. B. Saelinger (1985) Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infection and Immunity 50: 721-727.
|
60 |
Qureshi, N., P. Mascagni, E. Ribi, and K. Takayama (1985) Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595: purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. The Journal of Biological Chemistry 260: 5271-5278.
|
61 |
Rappuoli, R. (1983) Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197. Applied and Environmental Microbiology 46: 560-564.
|
62 |
Rappuoli, R. (1990) New and Improved Vaccines Against Diphtheria and Tetanus. pp. 251-269. In: M. M. Levine, M. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds.). New Generation Vaccines: Marcell Dekker, NY, USA.
|
63 |
Bell, F., A. Martin, C. Blondeau, C. Thornton, J. Chaplais, and A. Finn (1996) Combined diphtheria, tetanus, pertussis, and Heamophilus influenzae type b vaccines for primary immunization. Archives of Disease in Childhood 75: 298-303.
DOI
ScienceOn
|
64 |
Arya, S. C. (1994) Human immunization in developing countries: practical and theoretical problems and prospects. Vaccine 12: 1423-1435.
DOI
ScienceOn
|
65 |
Atmar, R. L. and W. A. Keitel (2009) Adjuvants for pandemic influenza vaccines. Current Topics in Microbiology and Immunology 333: 323-344.
DOI
|
66 |
Bae, K., J. Choi, Y. Jang, S. Ahn, and B. Hur (2009) Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Archives of Pharmacal Research 32: 465-480.
DOI
|
67 |
Belsey, M. A. (1970) Isolation of Corynebacterium diphtheriae in the environment of skin carriers. American Journal of Epidemiology 91: 294-299.
|
68 |
Botet Asensi, F. I., A. Veronese, M. Del Carmen Otero, M. Desamparados Tamarit Pérez, J. L. Hontangas Lopez, and S. Viviani (2003) Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. Acta Paediatrica 92: 541-545.
DOI
ScienceOn
|
69 |
Brandau, D. T., L. S. Jones, C. M. Wiethoff, J. Rexroad, and C. R. Middaugh (2003) Thermal stability of vaccines. Journal of Pharmaceutical Sciences 92: 218-231.
|
70 |
Rappuoli, R. (1997) New and improved vaccines against diphtheria and tetanus. pp. 417-435. In: M. M. Levine, M. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds.). New Generation Vaccines: Marcell Dekker, NY, USA.
|
71 |
Relyveld, E. H. (1969) Studies on the detoxification of purified diphtheria toxin. Progress in Immunobiological Standardization 3: 258-263.
|
72 |
Relyveld, E. H., B. Bizzini, and R. K. Gupta (1998) Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 16: 1016-1023.
DOI
ScienceOn
|
73 |
Carroll, S. F., J. T. Barbieri, and R. J. Collier (1988) Diphtheria toxin: purification and properties. Methods in Enzymology 165: 68-76.
DOI
|
74 |
Braun, L. J., A. Tyagi, S. Perkins, J. Carpenter, D. Sylvester, M. Guy, D. Kristensen, and D. Chen (2009) Development of a freeze-stable formulation for vaccine containing aluminum salt adjuvants. Vaccine 27: 72-79.
DOI
ScienceOn
|
75 |
Buzzi, S., D. Rubboli, G. Buzzi, A. M. Buzzi, C. Morisi, and F. Pironi (2004) CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunology, Immunotherapy 53:1041-1048.
|
76 |
Buzzi, S., G. Buzzi, A. M. Buzzi, and S. Martini (2007) CRM197: reduction of atherosclerotic stenoses in carotids of three elderly patients. Therapy 4: 293-298.
DOI
ScienceOn
|
77 |
Atkinson, W., J. Hamborsky, L. McIntyre, and S. Wolfe (2007) Epidemiology and Prevention of Vaccine-preventable Diseases (the pink book), 10th ed., pp. 59-70. Centers for Disease Control and Prevention, Public Health Foundation, Washington DC, USA.
|
78 |
Rydell, N. and I. Sjöholm (2005) Mucosal vaccination against diphtheria using starch microparticles as adjuvant for crossreacting material (CRM197) of diphtheria toxin. Vaccine 23: 2775-2783.
DOI
ScienceOn
|
79 |
Rennels, M. B., K. M. Edwards, H. L. Keyserling, K. Reisinger, M. M. Blatter, S. A. Quataert, D. V. Madore, I. Chang, F. J. Malinoski, J. G. Hackell, and P. R. Paradiso (2001) Safety and immunogenicity of four doses of neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. The Pediatric Infectious Disease Journal 20: 153-159.
DOI
ScienceOn
|
80 |
Rescia, V. C., C. S. Takata, P. S. de Araujo, and M. H. Bueno da Costa (2011) Dressing liposomal particles with chitosan and poly (vinylic alcohol) for oral vaccine delivery. Journal of Liposome Research 21: 38-45.
DOI
ScienceOn
|
81 |
Rydell, N. and I. Sjoholm (2004) Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22: 1265-1274.
DOI
ScienceOn
|
82 |
Chen, W. C. And L. Huang (2005) Non-viral vector as vaccine carrier. Advances in Genetics 54: 315-337.
DOI
|
83 |
Cerdeno-Tarraga, A. M., A. Efstratiou, L. G. Dover, M. T. Holden, M. Pallen, S. D. Bentley, G. S. Besra, C. Churcher, K. D. James, A. De Zoysa, T. Chillingworth, A. Cronin, L. Dowd, T. Feltwell, N. Hamlin, S. Holroyd, K. Jagels, S. Moule, M. A. Quail, E. Rabbinowitsch, K. M. Rutherford, N. R. Thomson, L. Unwin, S. Whitehead, B. G. Barrell, and J. Parkhill (2003) The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129. Nucleic Acids Research 31: 6516-6523.
DOI
|
84 |
Chen, D., C. A. Erickson, R. L. Endres, S. B. Periwal, Q. Chu, C. Shu, Y. F. Maa, and L. G. Payne (2001) Adjuvantation of epidermal powder immunization. Vaccine 19: 2908-2917.
DOI
ScienceOn
|
85 |
Chen, D., A. Tyagi, J. Carpenter, S. Perkins, D. Sylvester, M. Guy, D. D. Kristensen, and L. J. Braun (2009) Characterization of the freeze sensitivity of a hepatitis B vaccine. Human Vaccines 5: 26-32.
DOI
ScienceOn
|
86 |
Clausi, A., J. Cummiskey, S. Merkley, J. F. Carpenter, L. J. Braun, and T. W. Randolph (2008) Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. Journal of Pharmaceutical Sciences 97: 5252-5262.
DOI
ScienceOn
|
87 |
Rydell, N. and I. Sjoholm (2005) Mucosal vaccination against diphtheria using starch microparticles as adjuvant for crossreacting material (CRM197) of diphtheria toxin. Vaccine 23: 2775-2783.
DOI
ScienceOn
|
88 |
Rydell, N., L. Stertman,G. Stalenheim, and I. Sjoholm (2006) Use of an oral diphtheria vaccine in human. Vaccine 24: 5928-5930.
DOI
ScienceOn
|
89 |
Sato, H. and M. Takahashi (1996) Diphtheria Toxoid (diphtheria vaccine). pp. 52-59. In: Y. Arai, T. Asano, F. Chino, S. Katow, T. Miyamura, R. M. Nakamura, A. Oya, and H. Sato (eds.). Vaccine handbook: Maruzen, Tokyo, Japan.
|
90 |
Chodaczek, G. (2004) Adjuvants as factors improving efficiency of vaccination. Postey higieny i medycyny doswiadczalnej 58: 47-59.
|
91 |
Collier, R. J. (1975) Diphtheria toxin: mode of action and structure. Bacteriological Reviews 39: 54-85.
|
92 |
Collier, R. J. (2001) Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon 39: 1793-1803.
DOI
ScienceOn
|
93 |
Crane, D. T., B. Bolgiano, and C. Jones (1997) Comparison of the diphtheria mutant toxin, CRM197, with a Haemophilus influenzae type-b polysaccharide-CRM197 conjugate by optical spectroscopy. European Journal of Biochemistry 246: 320-327.
DOI
ScienceOn
|
94 |
Setia, S., H. Mainzer, M. L. Washington, G. Coil, R. Snyder, and B. G. Weniger (2002) Frequency and causes of vaccine wastage. Vaccine 20: 1148-1156.
DOI
ScienceOn
|
95 |
Shearer, G. M. and M. Clerici (1997) Vaccine strategies: selective elicitation of cellular or humoral immunity?. Trands in Biotechnology 15: 106-109.
DOI
ScienceOn
|
96 |
Shen, N. L., J. Hartikka, N. A. Horn, M. Manthorpe, and M. Marquet (2000) Development and characterization of lyophilized DNA vaccine formulations. Methods in Molecular Medicine 29: 23-34.
|
97 |
Cooper, P. D. (1994) The Selective Induction of Different Immune Responses by Vaccine Adjuvants. pp. 125-158. In: G. L. Ada (eds.). Strategies in Vaccine Design, Landes, Austin, TX, USA.
|
98 |
Corbel, M. J. (1996) Reasons for instability of bacterial vaccines. Developments in Biological Standardization 87: 113-124.
|
99 |
Crosbie, W. E. and H. D. Wright (1941) Diphtheria bacilli in floor dust. Lancet 237: 656-659.
DOI
ScienceOn
|
100 |
Danilova, E., A. Shiryayev, V. Skogen, E. K. Kristoffersen, and H. Sjursen (2005) Short-term booster effect of diphtheria toxoid in initially long-term protected individuals. Vaccine 23: 1446-1450.
DOI
ScienceOn
|
101 |
Deeks, E. D. (2010) Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults. Bio. Drugs 24: 287-297.
|
102 |
Ding, Z., E. Van Riet, S. Romeijn, G. F. Kersten, W. Jiskoot, and J. A. Bouwstra (2009) Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharmaceutical Research 26: 1635-1643.
DOI
ScienceOn
|
103 |
Showalter, S. L., Y. H. Huang, A. Witkiewicz, C. L. Costantino, C. J. Yeo, J. J. Green,R. Langer, D. G. Anderson, J. A. Sawicki, and J. R. Brody (2008) Nanoparticulate delivery of diphtheria toxin DNA effectively kills mesothelin expressing pancreatic cancer cells. Cancer Biology & Therapy 7: 1584-1590.
DOI
ScienceOn
|
104 |
Simerska, P., P. M. Moyle, C. Olive, and I. Toth (2009) Oral vaccine delivery-new strategies and technologies. Current Drug Delivery 6: 347-358.
DOI
ScienceOn
|
105 |
Sing, O. (2008) Immunogenicity and safety of DTPw-hepatitis B combined vaccines. Indian Pediatrics 45: 815-816.
|
106 |
Del Giudice, G., M. Pizza, and R. Rappuoli (1998) Molecular basis of vaccination. Molecular Aspects of Medicine 19: 1-70.
DOI
ScienceOn
|
107 |
Ding, Z., S. M. Bal, S. Romeijn, G. F. Kersten,W. Jiskoot, and Bouwstra (2011) Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array. Pharmaceutical Research 28: 145-158.
DOI
ScienceOn
|
108 |
Efstratiou, A. and R. C. George (1999) Laboratory guidelines for the diagnosis of infections caused by Corynebacterium diphtheriae and C. ulcerans. Communicable Disease and Public Health 2: 250-257.
|
109 |
Efstratiou, A., K. H. Engler, and A. De Zoysa (1998) Diagnosis and epidemiology of diphtheria. Methods in Molecular Medicine 15: 191-212.
|
110 |
Eldridge, J. H., R. M. Gilley, J. K. Staas, Z. Moldoveanu, J. A. Meulbroek, and T. R. Tice (1989) Biodegradable microspheres: vaccine delivery system for oral immunization. Current Topics in Microbiology and Immunology 146: 59-66.
DOI
|
111 |
El Sahly, H. (2010) as a vaccine adjuvant: a review of safety and immunogenicity. Expert Review of Vaccines 9: 1135-1141.
DOI
ScienceOn
|
112 |
Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, P., R. Kohberger, G. Siber, and P. H. Makela (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. The New England Journal of Medicine 344: 403-409.
DOI
ScienceOn
|
113 |
Garcon, N., P. Chomez, and M. Van Mechelen (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Review of Vaccines 6: 723-739.
DOI
ScienceOn
|
114 |
Singh, J., S. Pandit,V. W. Bramwell, and H. O. Alpar (2006) Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38: 96-105.
DOI
ScienceOn
|
115 |
Felnerova, D., J. F. Viret, R. Gluck, and C. Moser (2004) Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current Opinion in Biotechnology 15: 518-529.
DOI
ScienceOn
|
116 |
Flebbe, L. M. and H. Braley-Mullen (1986) Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. Cellular Immunology 99: 119-127.
DOI
ScienceOn
|
117 |
Fratelli, F., J. Abrahao-Neto, A. T. Caricati, M. M. Borges, R. Guidolin, and C. P. Caricati (2011) An alternative method for purifying and detoxifying diphtheria toxin. Toxicon 57: 1093-1100.
DOI
ScienceOn
|
118 |
Galazka, A., J. Milstien, and M. Zaffran (1998) Thermostability of vaccines, World Health Organization, Geneva. Switzerland.
|
119 |
Gardner, P. (2001) Issues related to the decennial tetanusdiphtheria toxoid booster recommendations in adults. Infectious Disease and Clinics of North America 15: 143-153.
DOI
ScienceOn
|
120 |
Soria-Guerra, R. E., S. Rosales-Mendoza, C. Marquez-Mercado, R. Lopez-Revilla, R. Castillo-Collazo, and A. G. Alpuche-Solis (2007)Transgenic tomatoes express an antigenic polypeptide containing epitopes of the diphtheria, pertussis and tetanus exotoxins, encoded by a synthetic gene. Plant Cell Reports 26: 961-968.
DOI
ScienceOn
|
121 |
Stickings, P., M. Peyre, L. Coombes, S. Muller, R. Rappuoli, G. Del Giudice, C. D. Partidos, and D. Sesardic (2008) Transcutaneous immunization with cross-reacting material CRM (197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine. Infection and Immunity 76: 1766-1773.
DOI
ScienceOn
|
122 |
Grabenstein, J. D. (2010) Toxoid Vaccines, pp. 105-124. In: A. W. Artenstein (eds.). Vaccines: A Biography. Springer, NY, USA.
|
123 |
Giannini, G., R. Rappuoli, and R. Ratti (1984) The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Research 12: 4063-4069.
DOI
ScienceOn
|
124 |
Glenny, A. T. and H. J. Sudmersen (1921) Notes on the production of immunity to diphtheria toxin. The Journal of Hygiene 20: 176-220.
DOI
|
125 |
Godefroy, S., M. Peyre, N. Garcia, S. Muller, D. Sesardic, and C. D. Partidos (2005) Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197) of diphtheria toxin. Infection and Immunity 73: 4803-4809.
DOI
ScienceOn
|
126 |
Gupta, R. K., R. J. Collier, R. Rappuoli, and G. R. Siber (1997) Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. Vaccine 15: 1341-1343.
DOI
ScienceOn
|
127 |
Gurunathan, S., C. Y. Wu, B. L. Freidag, and R. A. Seder (2000) DNA vaccines: a key for inducing long-term cellular immunity. Current Opinion in Immunology 12: 442-447.
DOI
ScienceOn
|
128 |
Hadfield, T. L., P. McEvoy, Y. Polotsky, V. A. Tzinserling, and A. A. Yakovlev (2000) The pathology of diphtheria. The Journal of Infectious Diseases 181: S116-S120.
DOI
|
129 |
Tsujioka, H., F. Yotsumoto, S. Hikita,T. Ueda, M. Kuroki, and S. Miyamoto (2011) Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Current Opinion in Obstetrics and Gynecology 23: 24-30.
DOI
ScienceOn
|
130 |
Strugnell, R. A., D. Drew, J. Mercieca, S. DiNatale, N. Firez, S. J. Dunstan, C. P. Simmons, and J. Vadolas (1997) DNA vaccines for bacterial infections. Immunology and Cell Biology 75: 364-369.
DOI
ScienceOn
|
131 |
Uchida, T., D. M. Gill, and A. M. Jr. Pappenheimer (1971) Mutation in the structural gene for diphtheria toxin carried by temperate phage. Nature: New Biology 233: 8-11.
DOI
ScienceOn
|
132 |
Tuteja, R. (1999) DNA vaccines: a ray of hope. Critical Reviews in Biochemistry and Molecular Biology 34: 1-24.
DOI
ScienceOn
|